ADC Therapeutics

/ADC Therapeutics

We are a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (“ADCs”) for patients suffering from hematological malignancies and solid tumors.

Symbol

Price Range
$23.00 - $26.00

Final Shares
8,164,000

Anticipated Date
October 3, 2019

Underwriters

This offering is no longer available

To view the prospectus for IPO, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277

Secured By miniOrange